{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:24:59Z","timestamp":1768735499519,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.cpcardiol.2022.101476","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T21:13:10Z","timestamp":1667250790000},"page":"101476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Integrating Cardiac MRI Imaging and Multidisciplinary Clinical Care is Associated With Improved Outcomes in Patients With Fabry Disease"],"prefix":"10.1016","volume":"48","author":[{"given":"Kevin","family":"Perera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niharika","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadya","family":"Omar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Easter","family":"Prosia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Ian","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nowell M.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-9028","authenticated-orcid":false,"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101476_bib0001","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0002","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry disease: JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0003","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0004","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J Med Genet"},{"issue":"FI2","key":"10.1016\/j.cpcardiol.2022.101476_bib0005","doi-asserted-by":"crossref","first-page":"f153","DOI":"10.1093\/europace\/eux261","article-title":"Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice","volume":"20","author":"Baig","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0006","first-page":"1041","article-title":"Comparison of cardiac magnetic resonance imaging and echocardiography in assessment of left ventricular hypertrophy in Fabry disease","volume":"34","author":"Hazari","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0007","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2147\/DDDT.S249433","article-title":"Analysis of renal and cardiac outcomes in male participants in the fabry outcome survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age","volume":"14","author":"Parini","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0008","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/gim.2016.55","article-title":"Is it Fabry disease?","volume":"18","author":"Schiffmann","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0009","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.21037\/cdt.2019.06.02","article-title":"Cardiovascular magnetic resonance imaging for structural heart disease","volume":"10","author":"Situ","year":"2020","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12968-015-0111-7","article-title":"Normal values for cardiovascular magnetic resonance in adults and children","volume":"17","author":"Kawel-Boehm","year":"2015","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0012","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1148\/radiol.2019191385","article-title":"Left ventricular hypertrophy and late gadolinium enhancement at cardiac MRI are associated with adverse cardiac events in Fabry disease","volume":"294","author":"Hanneman","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0013","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/heartjnl-2018-313699","article-title":"Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease","volume":"105","author":"Vijapurapu","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0014","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/heartjnl-2015-308494","article-title":"Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR","volume":"102","author":"Kozor","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13023-021-01894-2","article-title":"Development of the Fabry Disease Patient-Reported Outcome (FD-PRO): a new instrument to measure the symptoms and impacts of Fabry Disease","volume":"16","author":"Hamed","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0016","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jcmg.2020.03.004","article-title":"Longitudinal assessment of cardiac involvement in Fabry disease using cardiovascular magnetic resonance imaging","volume":"13","author":"Vijapurapu","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239675","article-title":"Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy","volume":"15","author":"Sadasivan","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0018","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1016\/j.ijcard.2012.06.069","article-title":"Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy","volume":"167","author":"Terryn","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0019","first-page":"883","article-title":"Clinical features, diagnosis, and management of patients with Anderson-Fabry cardiomyopathy","volume":"33","author":"Yogasundaram","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101476_bib0021","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.healun.2005.11.080","article-title":"Congestive heart failure in Fabry cardiomyopathy: natural history experience in an international cohort of 1,448 patients","volume":"25","author":"Pinderski","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0022","doi-asserted-by":"crossref","first-page":"e36373","DOI":"10.1371\/journal.pone.0036373","article-title":"Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease","volume":"7","author":"Namdar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009098","article-title":"Elevated inflammatory plasma biomarkers in patients with Fabry disease: a critical link to heart failure with preserved ejection fraction","volume":"7","author":"Yogasundaram","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0024","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","article-title":"Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study","volume":"126","author":"Weidemann","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0025","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with fabry disease natural history data from the fabry registry","volume":"57","author":"Patel","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0026","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1080\/1354750X.2018.1474261","article-title":"Circulating biomarkers of hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy assessed by cardiac magnetic resonance","volume":"23","author":"Gawor","year":"2018","journal-title":"Biomarkers"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0027","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0028","first-page":"e12083","article-title":"Stroke and Fabry disease: a review of literature","volume":"12","author":"Mishra","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094434","article-title":"Fabry disease and the heart: a comprehensive review","volume":"22","author":"Azevedo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0031","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jacc.2016.07.741","article-title":"Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy","volume":"68","author":"Nordin","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"8 Pt 2","key":"10.1016\/j.cpcardiol.2022.101476_bib0032","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","article-title":"Proposed stages of myocardial phenotype development in Fabry disease","volume":"12","author":"Nordin","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0033","first-page":"596","article-title":"Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children","volume":"36","author":"Rabi","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0034","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0035","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/ehjci\/jev057","article-title":"Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease","volume":"16","author":"Putko","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0036","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1161\/CIRCULATIONAHA.121.053527","article-title":"Time to think differently about sarcomere-negative hypertrophic cardiomyopathy","volume":"143","author":"Watkins","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0037","first-page":"173","article-title":"Major cardiovascular adverse events in Fabry disease patients receiving agalsidase alfa","volume":"81","author":"Ferrari","year":"2021","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0038","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ehjci\/jeaa101","article-title":"The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage","volume":"22","author":"Augusto","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0039","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10545-009-1156-2","article-title":"Can we use statins to prevent stroke in Fabry disease?","volume":"32","author":"Politei","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cpcardiol.2022.101476_bib0040","first-page":"3","article-title":"Lipid profile in adult patients with Fabry disease - ten-year follow up","volume":"13","author":"Stepien","year":"2017","journal-title":"Mol Genet Metab Rep"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622003735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622003735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:59:07Z","timestamp":1758938347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622003735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0146280622003735"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101476","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating Cardiac MRI Imaging and Multidisciplinary Clinical Care is Associated With Improved Outcomes in Patients With Fabry Disease","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101476"}}